ATRC Stock Analysis
AT
Uncovered
AtriCure Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
AtriCure, Inc. provides technologies for the treatment of atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain. The Company develops, manufactures and sells devices designed primarily for the surgical ablation of cardiac tissue, systems designed for the exclusion of the LAA and devices designed to block pain by temporarily ablating peripheral nerves. These devices are developed and marketed to medical centers. Its ablation and left atrial appendage (LAA) management products are used by physicians during both open-heart and minimally invasive procedures. Its products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System.